Sibaja JJD

Idioma: Español
Referencias bibliográficas: 17
Paginas: 513-516
Archivo PDF: 218.56 Kb.

RESUMEN

La selección de una terapia antimicrobiana inicial adecuada es fundamental para determinar el curso de las infecciones bacterianas severas. El surgimiento de los carbapenems, entre ellos Meropenem, como antibióticos β-lactámicos de amplio espectro, constituye una opción a considerar como terapia empírica inicial para el manejo de infecciones bacterianas severas en pacientes hospitalizados, respaldado por su eficacia terapéutica comprobada, seguridad y tolerabilidad.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Datos de Archivo, AstraZeneca, 2008.

2. Electronic medicines compendium. Meronem IV 500mg & 1g, summary of product characteristics from the electronic medicines compendium [online]. Disponible en URL: http:// www.emc medicines.org.uk/ [Accesado 2011 Dic 05]

3. Jones RN, Mendes C, Turner PJ, et al. An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997- 2004. Diagn Microbiol Infect Dis 2005 Dec; 53 (4): 247-56MerremRM IV (meropenem for injection): US Prescribing Information. AstraZeneca, 2007 Feb

4. Jones RN, Sader HS, Fritsche TR. Comparative activity of doripenem and three other carbapenems tested against gram- negative bacilli with various betalactamase resistance mechanisms. Diagn Microbiol Infect Dis 2005; 52: 71-4

5. Kollef MH. Appropriate empirical antibacterial therapy for nosocomial infections: getting it right the first time. Drugs 2003; 63 (20): 2157

6. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000 Sep; 31 Suppl. 4: S131-8

7. Lowe MN, Lamb HM. Meropenem: an updated review of its use in the management of intra-abdominal infections. Drugs 2000;60: 619-46

8. Merrem/MeronemTM (IV, 500mg, 1g): core data sheet. AstraZeneca, 2006 Sep

9. MerremRM IV (meropenem for injection): US Prescribing Information. AstraZeneca, 2007 Feb

10. Moon YSK, Chung KC, Gill MA. Pharmacokinetics of meropenem in animals, healthy volunteers, and patients. Clin Infect Dis 1997 Feb; 24 (Suppl. 2): 249-55

11. Nichols RL, Smith JW, Geckler RW, et al. Meropenem versus imipenem/cilastin in the treatment of hospitalized patients with skin and soft tissue infections. South Med J 1995 Apr; 88 (4):397-404

12. Rello J, Gallego M, Mariscal D, et al. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997 Jul; 156 (1): 196-200

13. Shah PM, Heller A, Fuhr HG, et al. Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients. Infection 1996; 24 (6): 480-4

14. Spriet I, Goyens J, Meersseman W, et al. Interaction between valproate and meropenem: a retrospective study. Ann Pharmacother 2007; 41 (7-8): 1130-6

15. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005 Nov 15; 41 (10): 1373-406

16. Tumbarello M, Sanguinetti M, Montuori E, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamaseproducing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007 Jun; 51 (6): 1987-94

17. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs 2007; 67 (7): 1027-52